Monte Rosa Therapeutics, Inc. (GLUE)
14.07
-0.25
(-1.75%)
USD |
NASDAQ |
Sep 11, 16:00
14.10
+0.03
(+0.21%)
Pre-Market: 20:00
Monte Rosa Therapeutics Enterprise Value : 616.02M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 616.02M |
| September 10, 2026 | 637.32M |
| September 09, 2026 | 632.21M |
| September 08, 2026 | 633.06M |
| September 04, 2026 | 596.42M |
| September 03, 2026 | 642.44M |
| September 02, 2026 | 628.80M |
| September 01, 2026 | 636.47M |
| August 31, 2026 | 604.94M |
| August 28, 2026 | 557.21M |
| August 27, 2026 | 637.32M |
| August 26, 2026 | 642.44M |
| August 25, 2026 | 657.78M |
| August 24, 2026 | 590.88M |
| August 21, 2026 | 635.62M |
| August 20, 2026 | 676.53M |
| August 19, 2026 | 760.90M |
| August 18, 2026 | 697.84M |
| August 17, 2026 | 727.66M |
| August 14, 2026 | 737.89M |
| August 13, 2026 | 766.87M |
| August 12, 2026 | 776.24M |
| August 11, 2026 | 760.05M |
| August 10, 2026 | 765.16M |
| August 07, 2026 | 770.28M |
| Date | Value |
|---|---|
| August 06, 2026 | 755.79M |
| August 05, 2026 | 747.27M |
| August 04, 2026 | 787.32M |
| August 03, 2026 | 727.66M |
| July 31, 2026 | 824.82M |
| July 30, 2026 | 1.350B |
| July 29, 2026 | 1.254B |
| July 28, 2026 | 1.295B |
| July 27, 2026 | 1.340B |
| July 24, 2026 | 1.358B |
| July 23, 2026 | 1.380B |
| July 22, 2026 | 1.444B |
| July 21, 2026 | 1.431B |
| July 20, 2026 | 1.418B |
| July 17, 2026 | 1.510B |
| July 16, 2026 | 1.391B |
| July 15, 2026 | 1.412B |
| July 14, 2026 | 1.416B |
| July 13, 2026 | 1.290B |
| July 10, 2026 | 1.380B |
| July 09, 2026 | 1.507B |
| July 08, 2026 | 1.467B |
| July 07, 2026 | 1.496B |
| July 06, 2026 | 1.398B |
| July 02, 2026 | 1.480B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ironwood Pharmaceuticals, Inc. | 991.92M |
| Capricor Therapeutics, Inc. | 339.48M |
| Cue Biopharma, Inc. | 141.71M |
| Nurix Therapeutics, Inc. | 2.218B |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.40M |
| Revenue (Quarterly) | 8.968M |
| Total Expenses (Quarterly) | 52.36M |
| EPS Diluted (Quarterly) | -0.4276 |
| Gross Profit Margin (Quarterly) | 78.69% |
| Profit Margin (Quarterly) | -483.9% |
| Earnings Yield | -13.55% |
| Normalized Earnings Yield | -13.54 |